603233.SH上海证券交易所 · 主板 Main
DaShenLin Pharmaceutical Group 大参林
Pharmaceutical Distribution 医药商业
¥17.55−¥0.42 · −2.34%
Open 开盘
¥18.00
High 最高
¥18.21
Low 最低
¥17.51
Prev Close 昨收
¥17.97
Volume 成交量
744.8万股
Turnover 成交额
¥1.32亿
Mkt Cap 总市值
¥200亿
P/E 市盈率
14.7×
Recent Activity 近期动态All Filings 全部公告 →
12 significant filings since 29 May 2026: 2 on regulatory inquiry, 4 on dividend and 2 on guarantee or financial assistance, and 3 other kinds. The latest, on 25 Aug 2026: 大参林医药集团股份有限公司关于2026年半年度利润分配方案的公告.
自 29 May 2026 起有 12 份重大公告：regulatory inquiry 2 份、dividend 4 份、guarantee or financial assistance 2 份，另有 3 类。最新一份（25 Aug 2026）：大参林医药集团股份有限公司关于2026年半年度利润分配方案的公告。
15.0016.0017.0018.0019.0020.00
Volume 成交量
2,114.5万
Sep 25Dec 25Mar 26Jun 26Sep 26
Overview 概览Deep Report 深度报告Financials 财务Valuation 估值Ownership 股东Analysts 券商Estimates 预测News 动态Events 事件Peers 同业
Relative Value 同业比较
Pharmaceutical Distribution 医药商业 · 30 listed peers
| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥200亿 | ¥59亿 | 4th highest of 30 · 30 家中第 4 高 | |
| Trailing P/E 市盈率 | 14.7x | 22.9x | 8th lowest of 25 · 25 家中第 8 低 | |
| P/B 市净率 | 2.6x | 1.2x | 9th highest of 30 · 30 家中第 9 高 | |
| Revenue Growth 营收增速 | 3.5% | 0.3% | 9th highest of 30 · 30 家中第 9 高 | |
| Profit Growth 净利增速 | 16.1% | -7.2% | 6th highest of 30 · 30 家中第 6 高 | |
| Gross Margin 毛利率 | 35.6% | 11.2% | 4th highest of 30 · 30 家中第 4 高 | |
| Net Margin 净利率 | 7.2% | 1.6% | 3rd highest of 30 · 30 家中第 3 高 | |
| Return on Equity 净资产收益率 | 11.6% | 3.0% | Highest of 30 · 30 家中第 1 高 | |
| Debt to Assets 资产负债率 | 65.0% | 61.0% | 12th highest of 30 · 30 家中第 12 高 | |
| Grade Score 评级得分 | 71 | 47 | 2nd highest of 30 · 30 家中第 2 高 |
Statement figures are for the period to 30 Jun 2026, filed by 30 of 30 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，30 家同业中 30 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
Largest Peers 主要同业
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Shanghai Pharma 上海医药 | ¥594亿 | 12.4x | 0.8x | 4.2% | 2.9% | 4.5% | C |
| Yifeng Pharmacy 益丰药房 | ¥268亿 | 15.2x | 2.3x | 3.5% | 8.8% | 8.0% | B |
| Jointown 九州通 | ¥244亿 | 12.1x | 0.9x | 7.6% | 1.4% | 4.2% | D |
| DaShenLin Pharmaceutical Group 大参林 | ¥200亿 | 14.7x | 2.6x | 3.5% | 7.2% | 11.6% | B |
| China National Medicines 国药股份 | ¥194亿 | 10.1x | 1.0x | 4.3% | 3.3% | 4.7% | C |
| Qingdao Baheal Medical 百洋医药 | ¥133亿 | 24.7x | 5.8x | -5.1% | 7.9% | 9.3% | C |
| China Meheco 中国医药 | ¥133亿 | 30.9x | 1.1x | -0.7% | 1.8% | 2.1% | D |
| China National Accord Medicines 国药一致 | ¥119亿 | 11.1x | 0.6x | -1.4% | 1.8% | 3.2% | D |
| Lbx Pharmacy Chain 老百姓 | ¥98亿 | 22.8x | 1.4x | 2.1% | 4.8% | 6.6% | C |
| C.Q. Pharmaceutical Holding 重药控股 | ¥89亿 | 24.8x | 0.8x | -2.6% | 0.8% | 2.2% | E |
| Shanghai C&D Innostic Medical Technology 建发致新 | ¥83亿 | 29.7x | 3.8x | 1.8% | 1.9% | 6.8% | D |
| Nanjing Pharmaceutical Group 南京医药 | ¥64亿 | 10.2x | 0.9x | -0.5% | 1.4% | 4.0% | D |
| Yixintang Pharmaceutical Group 一心堂 | ¥62亿 | 22.9x | 0.8x | -5.0% | 3.1% | 3.5% | C |
| Guangxi Liuyao Group 柳药集团 | ¥60亿 | 9.3x | 0.8x | 2.2% | 3.5% | 4.6% | C |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。